Wechselwirkungen · Anoro Ellipta (previously Anoro)
ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed · Abschnitt 4.5 · PDF-Seite 5
HOS-129129 · Präparat HOS-096681
Both umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The effect of the moderate P-gp inhibitor verapamil (240 mg once daily) on the steady-state pharmacokinetics of umeclidinium and vilanterol was assessed in healthy volunteers. No effect of verapamil was observed on umeclidinium or vilanterol Cmax. An approximately 1.4-fold increase in umeclidinium AUC was observed with no effect on vilanterol AUC. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when umeclidinium/vilanterol is co-administered with P-gp inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-31T09:00:00Z · SHA-256 55532081e38077e14b6448f7cc246b93ec49bd5a6fa1e010be00e4a9b8e25695 · Passage 017d1cbb5e480a77fbec27ad3165732fb073f14513f69c1cf555adbe33dcff91 · Zeichen 2147–2749 im Abschnitt